What We're Reading: Page 374
Industry reads hand-picked by our editors
Jan 12, 2015
-
Reuters
How one hedge fund manager plans to take on big pharma patents
-
-
-
-
Biogen Idec's novel optical nerve repair therapy shows promise, but only some
-
-
Finally approved: FDA says 'yes' to Impax's Parkinson's drug
-
-
Tensions with pharma run high as UK's Cancer Drugs Fund cuts expenses
-
Novartis seeks FDA approval for two smoker's cough drugs
Jan 09, 2015
-
The first groundbreaking antibiotic in 25 years may literally come out of the ground
-
-
-
Siga ordered to pay $113M to PharmaAthene in smallpox case
-
-
Namenda controversy continues as Actavis awaits court decision
-
-
-
Study reveals no Gardasil-MS link
-
Novartis OTC advertising under fire after Pfizer complaint
Jan 08, 2015
Jan 07, 2015
-
-
UPDATE: Novartis Neupogen biosimilar takes yet another step toward FDA approval
-
-
Minnesota Investment Board will not support Medtronic-Covidien inversion deal
-
-
Moderna raises record $450M from investors with groundbreaking RNA tech
-
Salix CEO Logan becomes second C-suite casualty of inventory spat
-
NIH awards $28 million in grants to unlock mysteries of gene regulation
-
-
J&J and Isis strike $835 million co-development deal
Jan 06, 2015
-
-
Japan first nation to approve potential Novartis blockbuster Cosentyx
-
An 18-year record: FDA approved 41 drugs in 2014
-
-
Promising late-stage trial bodes well for Cempra's next-gen antibiotic
-
Massachusetts mulls legal action over marketing practices for pain drugs
-
-
Chiasma raising $56M to develop acromegaly drug—without Roche
-
-
Out with the old: Novartis completes Lilly animal health sale as part of overhaul
Jan 05, 2015
Dec 23, 2014
-
UPDATED: Express Scripts snubs Gilead, will only offer AbbVie's new hep C pill
-
-
-
FDA approves Cubist's novel antibiotic Zerbaxa for complicated infections
-
Actavis considering Almirall acquisition to expand European foothold
-
-
FDA unexpectedly approves AZ's Lynparza for advanced ovarian cancer
-
-
-
CVS Health: Harvoni being prescribed at 2.5 times the rate of Sovaldi
Previous
